LOGIN  |  REGISTER
Assertio

NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th

March 19, 2025 | Last Trade: US$2.25 0.08 3.78
  • Management will host a conference call at 4:30 p.m. ET on the same day

LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.

Fourth Quarter and Full Year 2024 Financial Results Conference Call
Date: March 24, 2025
Time: 4:30 p.m. ET
Live Call: 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through April 3, 2025 by dialing 1-844-512-2921(U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11158402. An archive of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page